Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.

[1]  F. Greene.  AJCC cancer staging handbook , 2002 .

[2]  K. Rosenzweig,et al.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[3]  D. Sugarbaker,et al.  Malignant pleural mesothelioma. , 2001, Cancer treatment and research.

[4]  R. Hawkins,et al.  Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. , 2000, The Journal of thoracic and cardiovascular surgery.

[5]  C B Begg,et al.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. , 1999, AJR. American journal of roentgenology.

[6]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[7]  A. Alavi,et al.  Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.

[8]  V. Rusch,et al.  The importance of surgical staging in the treatment of malignant pleural mesothelioma. , 1996, The Journal of thoracic and cardiovascular surgery.

[9]  V. Rusch.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[10]  D. Sugarbaker,et al.  Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. , 1992, AJR. American journal of roentgenology.